Investigational drug · Phase 2
ASTX660
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumors, Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
11
Any phase or sponsor naming "ASTX660"
First trial start
2015
Jul 14, 2015
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASTX660", any sponsor or status.
- Phase 111
Conditions studied
As listed on its trial records.
- Solid Tumors
- Lymphoma
Approved drugs for the same conditions: Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "ASTX660" as an intervention, largest first.
- Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasPivotal-lookingActive, not recruiting
Taiho Oncology, Inc.Industry
NCT02503423 · 253 participants · Start Jul 14, 2015 · Primary completion Oct 2022
Drug: ASTX660 · For: Solid Tumors; Lymphoma
Sites: Birmingham, Alabama; Scottsdale, Arizona; Los Angeles, California · 68 sites in all
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT05912075 · 78 participants (planned) · Start Dec 19, 2023 · Primary completion Jan 1, 2028
Drug: mFOLFIRINOX; Capecitabine and 3 more · For: Locally-advanced Rectal Cancer
Sites: Lyon, France; Villejuif, France
Astex Pharmaceuticals, Inc.Industry
NCT04155580 · 68 participants · Start Jun 12, 2020 · Primary completion Jan 14, 2022
Drug: ASTX660; ASTX727 · For: Acute Myeloid Leukemia
Sites: San Francisco, California; New Haven, Connecticut; Miami, Florida · 15 sites in all
- ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabActive, not recruiting
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT05082259 · 61 participants (planned) · Start Mar 2, 2022 · Primary completion Dec 2026
Drug: ASTX660; Pembrolizumab · For: Advanced Cancer; Cervical Cancer; Triple Negative Breast Cancer
Sites: Cambridge, United Kingdom; Sutton, United Kingdom · 3 sites in all
Astex Pharmaceuticals, Inc.Industry
NCT04411030 · 36 participants · Start May 20, 2020 · Primary completion Aug 23, 2020
Drug: ASTX660; Midazolam and 1 more · For: Healthy Volunteer
Sites: Springfield, Missouri
Taiho Oncology, Inc.Industry
NCT05403450 · 33 participants · Start Feb 22, 2023 · Primary completion Dec 16, 2024
Drug: Tolinapant; Decitabine + Cedazuridine · For: Relapsed/Refractory Peripheral T-cell Lymphoma
Sites: Aurora, Colorado; Tampa, Florida; Atlanta, Georgia · 19 sites in all
Astex Pharmaceuticals, Inc.Industry
NCT04479800 · 21 participants · Start Jul 20, 2020 · Primary completion Aug 25, 2020
Drug: ASTX660 · For: Healthy Volunteer
Sites: San Antonio, Texas
- Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck CancerActive, not recruiting
Emory UniversityAcademic, hospital or other
NCT05245682 · 10 participants · Start Feb 17, 2022 · Primary completion Jan 15, 2024
Drug: Tolinapant · For: Head and Neck Carcinoma of Unknown Primary; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hypopharyngeal Squamous Cell Carcinoma and 3 more
Sites: Atlanta, Georgia
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT04362007 · 8 participants · Start Jul 14, 2020 · Primary completion Nov 30, 2024
Drug: ASTX660; ASTX660 and 1 more · For: Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
Sites: Yamagata, Japan
National Cancer Institute (NCI)NIH
NCT06590558 · 0 participants · Start Aug 4, 2025 · Primary completion May 17, 2027
Drug: Eribulin Mesylate; Tolinapant · For: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma and 9 more
Newest research
PubMed records naming it or its code names, newest first.
- IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial.
Tiu C, Yau W, Tenev T, et al. · Nat Commun 2026
- Translational investigation of tolinapant (ASTX660) in acute myeloid leukemia by integrating clinical, bioinformatic and pharmacological approaches.
Lima K, Nogueira FL, Reis-Silva CSM, et al. · Blood Res 2025
- Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer : a study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres.
Hoskin P, Lee M, Dunkley D, et al. · BMC Cancer 2024
- A validated liquid chromatography-tandem mass spectroscopy method for the quantification of tolinapant in human plasma.
Martins V, Wilsher N, Lin S, et al. · Anal Sci Adv 2022
- Novel smac mimetic ASTX660 (Tolinapant) and TNF-α synergistically induce necroptosis in bladder cancer cells in vitro upon apoptosis inhibition.
Wang L, Hu C, Zhao Y, et al. · Biochem Biophys Res Commun 2022
- Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma.
Ferrari N, Ward G, Gewinner C, et al. · Blood Adv 2021
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.